Pending FDA inspection at Indrad facility
When explicitly asked about regulatory status of Indrad facility, management confirmed it is still pending inspection. This remains an unresolved regulatory risk for the U.S. supply chain.
TORNTPHARM / Q3-FY24 / risks
Keep the risk register visible.
Torrent Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Intense competition in chronic therapeutic segments
Multiple peers expanding into diabetes, cardiac, gastro, and CNS segments where Torrent is strong. Management acknowledged increased competition but relied on new launch track record and field force expansion as defense.
U.S. Dahej capacity realignment incomplete
Some high-volume products shifted from Indrad to CMO to address Dahej constraints. While management expects new launches from Q1 FY25, the capacity optimization is still in progress with execution risk.
Forex translation losses of INR 35 crore
Other income includes INR 35 crore of Forex translation losses that management expects to reverse in coming quarters, introducing earnings volatility dependent on currency movements.